Tag Archives: Sanofi

Sanofi completes the divestment of its European generics business Zentiva to Advent

PARIS, 04-Oct-2018 — /EuropaWire/ — Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule for €1,9 billion (enterprise value). Sanofi announced the beginning … Read the full press release

Sanofi launches worldwide stock purchase plan reserved for its employees

A plan taking place in almost 80 countries Subscription per five shares entitle the employee to one matching share[1] PARIS, 12-Jun-2018 — /EuropaWire/ — Sanofi launches today “Action 2018”, a worldwide stock purchase plan reserved for its employees. In doing such a … Read the full press release

Dupixent demonstrated significant improvement in multiple asthma endpoints in two Phase 3 clinical trials

Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled asthma, irrespective of minimum baseline eosinophil levels or other biomarkers of Type 2 inflammation Greater … Read the full press release

John C. Reed, M.D. Ph.D. to succeed Elias Zerhouni, M.D. as Head of Global Research and Development at Sanofi

PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post … Read the full press release

Sanofi: the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for Sanofi’s acquisition of Bioverativ has expired

PARIS, 26-Feb-2018 — /EuropaWire/ — Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Bioverativ Inc. (“Bioverativ”, NASDAQ: BIVV) has expired. On February 7, … Read the full press release

Sanofi acquires Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders

Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases  Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders  Drives meaningful shareholder value with ROIC expected to exceed cost of … Read the full press release

Sanofi’s Toujeo® met primary objective in the first head-to-head clinical trial comparing Toujeo with insulin degludec

First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec PARIS, 05-Dec-2017 — /EuropaWire/ — Sanofi’s Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, … Read the full press release

Sanofi discontinues clinical development of its experimental Clostridium difficile vaccine

PARIS, 05-Dec-2017 — /EuropaWire/ — Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial program concluded that the probability that the study will meet its primary objective is low. Based on this, Sanofi has … Read the full press release

200 healthcare decision-makers gather to address the looming challenges of cost, access and sustainability in the coming wave of high-value medicines

LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies. The … Read the full press release

Sanofi: Phase 3 study on dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints

First study with a biologic to show benefit  in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline Pivotal program is first with a biologic to show consistent reductions … Read the full press release

Sanofi files patent infringement suit against Merck Sharp & Dohme Corp. in US

PARIS, 10-Aug-2017 — /EuropaWire/ — Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. (“Merck”) on August 8, 2017 in the United States District Court for the District of New Jersey. In its suit Sanofi … Read the full press release

Sanofi’s Soliqua™ 100/33 now available by prescription in U.S. for the treatment of adults with type 2 diabetes

PARIS, 04-Jan-2017 — /EuropaWire/ — Sanofi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults with type 2 … Read the full press release

Sanofi’s Merial and Boehringer Ingelheim’s CHC business swap successfully closed

Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017 — /EuropaWire/ — Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an … Read the full press release

Sanofi Pasteur and MSD to separately pursue their own vaccine strategies in Europe

PARIS, 03-Jan-2017 — /EuropaWire/ — Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their vaccine joint-venture with MSD (known as Merck & Co. Inc., in the United States and Canada), Sanofi Pasteur MSD (SPMSD). … Read the full press release

Sanofi welcomes Alan Main as EVP Consumer HealthCare

PARIS, 04-Oct-2016 — /EuropaWire/ — Sanofi today announced the appointment of Alan Main as Executive Vice President Consumer HealthCare, effective October 1st, 2016. Mr. Main will be a member of the Executive Committee and lead a newly created Consumer Healthcare … Read the full press release

Sanofi announces the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D

PARIS, 31-Mar-2016 — /EuropaWire/ — Sanofi announced today the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D, effective April 1, 2016. He will report to Dr. Elias Zerhouni, President, Global R&D. Dr. Liu is one of the world’s … Read the full press release

Dengue vaccine: Sanofi Pasteur’s Dengvaxia® receives regulatory approval in Brazil

Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic country – With 1.4 million dengue cases reported this year, Brazil stands to gain tremendous value from this new dengue … Read the full press release

Sanofi: LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with or without metformin

LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ —  Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release

Sanofi’s subsidiary Genzyme to acquire Caprelsa® (vandetanib) from AstraZeneca

Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France,  30-7-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a … Read the full press release

Sanofi, Regeneron Pharmaceuticals partner to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies – Sanofi commits to an initial investment of up to $2.17 billion in the exclusive collaboration, including $640 million in upfront payments to Regeneron … Read the full press release

Sanofi and its subsidiary Genzyme announced that US FDA granted Breakthrough Therapy designation to olipudase alfa

Investigational Enzyme Replacement Therapy to Treat Non-Neurological Manifestations which characterize Niemann-Pick Type B PARIS, 5-6-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. … Read the full press release

Robert Castaigne succeeds Dr. Klaus Pohle as Chairman of Sanofi’s Audit Committee

PARIS, 9-3-2015 — /EuropaWire/ — Sanofi today announced the appointment of Robert Castaigne as Chairman of its Audit Committee. Mr. Castaigne succeeds Dr. Klaus Pohle who has chaired Sanofi’s Audit Committee since 2004. This appointment is effective as of the Sanofi Board … Read the full press release

Sanofi and subsidiary Genzyme announced that FDA approved LemtradaTM (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS)

Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved LemtradaTM (alemtuzumab) for … Read the full press release

Sanofi and MyoKardia, Inc. join forces to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies

Up to $200 Million Collaboration to Support Pioneering Science and New Treatments Paris and South San Francisco, CA, 18-9-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic … Read the full press release

Sanofi and its subsidiary Genzyme announced positive interim results from the second year of the extension study of Lemtrada™ (alemtuzumab) for multiple sclerosis

In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year pivotal multiple sclerosis studies Approximately 70 percent of patients treated with Lemtrada did not receive a third course of treatment … Read the full press release

Sanofi: Genzyme’s Cerdelga™ capsules the only first-line oral therapy for certain adult Gaucher disease type 1 approved by FDA

Only First-Line Oral Treatment for Adult Gaucher Disease Type 1 Paris, 22-8-2014 — /EuropaWire/ — Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only … Read the full press release

Sanofi and PATH announced the market debut for the first antimalarial treatments produced with semisynthetic artemisinin

First shipment marks a critical step in improving access to treatment worldwide Paris, France, and South San Francisco, United States, 19-8-2014 — /EuropaWire/ — Sanofi (Euronext: SAN and NYSE: SNY) and PATH today announced the delivery of the first large-scale batches of … Read the full press release

Sanofi and Medtronic partner to improve patient experience and outcomes for people with diabetes around the world

Initial focus on insulin-device combinations and care management services Paris and Minneapolis, Minn., 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) today announced that they have signed a memorandum of understanding to enter into a … Read the full press release

Sanofi and Regeneron Pharmaceuticals presented positive results from Sarilumab Phase 3 Rheumatoid Arthritis Trial at European League Against Rheumatism Annual Congress in Paris

Both doses of investigational drug sarilumab met all three co-primary endpoints New data include major clinical response rates and ACR20 scores at 52 weeks Paris and Tarrytown, NY, 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, … Read the full press release

Sanofi’s investigational therapy Toujeo® consistently showed significantly fewer low blood sugar events compared with Lantus®

Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time compared with Lantus® All studies in the phase 3 “EDITION” clinical trial program, including a … Read the full press release